1. Emerging Targets for the Diagnosis of Cancer

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. An Introduction to NTRK

5. TRK Protein Expression in Normal Tissues

6. Timeline of Fusion Discoveries

7. NTRK Fusions

8. NTRK Rearrangements Common in Rare Neoplasms

9. Occurrence of NTRK Fusions Across Cancer Types

10. NTRK Testing Presents Challenges to Clinicians

11. NTRK IHC

12. Pan-TRK IHC -- Selected Studies Hechtman et al, Am J Surg Pathol, 2017

13. Pan-TRK IHC -- Selected Studies Hung et al, Histopathology, 2018

14. FISH for NTRK1/2/3

15. Diversity of NTRK1/2/3 Fusion Partners

16. NTRK1/2/3 Testing DNA-Based NGS

17. RNA-Based NGS Testing

18. Anchored Multiplex PCR: NTRK Fusion Detected by Archer®

19. DNA-NGS and RNA-NGS Are Complementary

20. Other Methods

21. Different Assays for NTRK Assessment Advantages and Disadvantages

22. TRK Inhibitors Are Highly Effective in NTRK Fusion-Positive Cancers

23. Larotrectinib in NTRK Fusion-Positive Cancers

24. Larotrectinib Efficacy Across Tumor Type

25. Durability of Response

26. Entrectinib in NTRK Fusion-Positive Cancers

27. Entrectinib ORR by Tumor Type

28. DoR, PFS, and OS With Entrectinib

29. Intracranial ORR With Entrectinib

30. Select TRAEs With Larotrectinib

31. Select TRAEs With Entrectinib

32. On-Target Resistance to First-Generation TRK Inhibitors

33. Overcoming TRK TKI Resistance With Second-Generation TRK Inhibitors

34. Selecting Appropriate Patients for TRK Inhibitors

35. Best Practices for Communicating Test Results Know Your Audience

36. Best Practices for Communicating Test Results CAP Checklist

37. Abbreviations

38. Abbreviations (cont)

39. Abbreviations (cont)